...
atha-img

Athira Pharma Inc, Common Stock

ATHA

NSQ

$0.623

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$24.17M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
50.09K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.83
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.41 L
$4.3 H
$0.623

About Athira Pharma Inc, Common Stock

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameATHASectorS&P500
1-Week Return-4.61%-1.57%0.77%
1-Month Return-16.67%-1.86%5.21%
3-Month Return11.23%-6.07%10.43%
6-Month Return-75.68%-0.47%13.46%
1-Year Return-64.39%10%32.91%
3-Year Return-95.17%10.67%32.22%
5-Year Return-96.35%45.46%94.57%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-2.00M479.00K1.05M969.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":23.95,"profit":true},{"date":"2022-12-31","value":52.4,"profit":true},{"date":"2023-12-31","value":48.45,"profit":true}]
Gross Profit-(2.00M)(479.00K)(1.05M)(969.00K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-200000000,"profit":false},{"date":"2021-12-31","value":-47900000,"profit":false},{"date":"2022-12-31","value":-104800000,"profit":false},{"date":"2023-12-31","value":-96900000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses4.70M18.67M55.19M88.86M125.47M[{"date":"2019-12-31","value":3.74,"profit":true},{"date":"2020-12-31","value":14.88,"profit":true},{"date":"2021-12-31","value":43.99,"profit":true},{"date":"2022-12-31","value":70.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(5.45M)(20.00M)(64.02M)(104.02M)(125.47M)[{"date":"2019-12-31","value":-544900000,"profit":false},{"date":"2020-12-31","value":-1999500000,"profit":false},{"date":"2021-12-31","value":-6402200000,"profit":false},{"date":"2022-12-31","value":-10401600000,"profit":false},{"date":"2023-12-31","value":-12546600000,"profit":false}]
Total Non-Operating Income/Expense(7.00K)(203.00K)9.50M10.13M-[{"date":"2019-12-31","value":-0.07,"profit":false},{"date":"2020-12-31","value":-2,"profit":false},{"date":"2021-12-31","value":93.77,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(5.16M)(19.95M)(54.85M)(95.64M)(117.67M)[{"date":"2019-12-31","value":-516100000,"profit":false},{"date":"2020-12-31","value":-1995500000,"profit":false},{"date":"2021-12-31","value":-5485300000,"profit":false},{"date":"2022-12-31","value":-9563900000,"profit":false},{"date":"2023-12-31","value":-11767200000,"profit":false}]
Income Taxes(459.00K)(1.32M)(479.00K)(8.38M)(1.63M)[{"date":"2019-12-31","value":-45900000,"profit":false},{"date":"2020-12-31","value":-132100000,"profit":false},{"date":"2021-12-31","value":-47900000,"profit":false},{"date":"2022-12-31","value":-837700000,"profit":false},{"date":"2023-12-31","value":-162800000,"profit":false}]
Income After Taxes(4.70M)(18.63M)(54.37M)(87.26M)-[{"date":"2019-12-31","value":-470200000,"profit":false},{"date":"2020-12-31","value":-1863400000,"profit":false},{"date":"2021-12-31","value":-5437400000,"profit":false},{"date":"2022-12-31","value":-8726200000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(5.16M)(19.95M)(54.85M)(100.80M)(117.67M)[{"date":"2019-12-31","value":-516100000,"profit":false},{"date":"2020-12-31","value":-1995500000,"profit":false},{"date":"2021-12-31","value":-5485300000,"profit":false},{"date":"2022-12-31","value":-10080000000,"profit":false},{"date":"2023-12-31","value":-11767200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(4.70M)(18.63M)(54.37M)(87.26M)(117.67M)[{"date":"2019-12-31","value":-470200000,"profit":false},{"date":"2020-12-31","value":-1863400000,"profit":false},{"date":"2021-12-31","value":-5437400000,"profit":false},{"date":"2022-12-31","value":-8726200000,"profit":false},{"date":"2023-12-31","value":-11767200000,"profit":false}]
EPS (Diluted)-(1.80)(1.50)(2.27)(3.09)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-180,"profit":false},{"date":"2021-12-31","value":-150,"profit":false},{"date":"2022-12-31","value":-227,"profit":false},{"date":"2023-12-31","value":-309,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ATHA
Cash Ratio 2.48
Current Ratio 2.95

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ATHA
ROA (LTM) -47.53%
ROE (LTM) -84.57%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ATHA
Debt Ratio Lower is generally better. Negative is bad. 0.33
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.67

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ATHA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.42
Price/FCF NM
EV/R 0.00
EV/Ebitda 1.31

FAQs

What is Athira Pharma Inc share price today?

Athira Pharma Inc (ATHA) share price today is $0.623

Can Indians buy Athira Pharma Inc shares?

Yes, Indians can buy shares of Athira Pharma Inc (ATHA) on Vested. To buy Athira Pharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATHA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Athira Pharma Inc be purchased?

Yes, you can purchase fractional shares of Athira Pharma Inc (ATHA) via the Vested app. You can start investing in Athira Pharma Inc (ATHA) with a minimum investment of $1.

How to invest in Athira Pharma Inc shares from India?

You can invest in shares of Athira Pharma Inc (ATHA) via Vested in three simple steps:

  • Click on Sign Up or Invest in ATHA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Athira Pharma Inc shares
What is Athira Pharma Inc 52-week high and low stock price?

The 52-week high price of Athira Pharma Inc (ATHA) is $4.3. The 52-week low price of Athira Pharma Inc (ATHA) is $0.41.

What is Athira Pharma Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Athira Pharma Inc (ATHA) is

What is Athira Pharma Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Athira Pharma Inc (ATHA) is 0.42

What is Athira Pharma Inc dividend yield?

The dividend yield of Athira Pharma Inc (ATHA) is 0.00%

What is the Market Cap of Athira Pharma Inc?

The market capitalization of Athira Pharma Inc (ATHA) is $24.17M

What is Athira Pharma Inc’s stock symbol?

The stock symbol (or ticker) of Athira Pharma Inc is ATHA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top